Charles River Laboratories Intl. Inc (NYSE:CRL) VP William D. Barbo Sells 6,901 Shares

Share on StockTwits

Charles River Laboratories Intl. Inc (NYSE:CRL) VP William D. Barbo sold 6,901 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $172.11, for a total transaction of $1,187,731.11. Following the completion of the sale, the vice president now directly owns 18,931 shares in the company, valued at $3,258,214.41. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Shares of CRL opened at $176.48 on Friday. Charles River Laboratories Intl. Inc has a 52 week low of $123.17 and a 52 week high of $176.89. The firm has a market cap of $8.44 billion, a P/E ratio of 34.88, a price-to-earnings-growth ratio of 1.91 and a beta of 1.18. The firm’s 50-day simple moving average is $157.46 and its 200 day simple moving average is $141.17. The company has a debt-to-equity ratio of 1.20, a quick ratio of 1.20 and a current ratio of 1.44.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $2.01 EPS for the quarter, beating the Zacks’ consensus estimate of $1.83 by $0.18. Charles River Laboratories Intl. had a net margin of 9.61% and a return on equity of 22.17%. The business had revenue of $691.10 million for the quarter, compared to analyst estimates of $685.46 million. During the same quarter in the prior year, the business earned $1.49 EPS. Charles River Laboratories Intl.’s quarterly revenue was up 14.1% on a year-over-year basis. As a group, equities analysts forecast that Charles River Laboratories Intl. Inc will post 7.54 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in CRL. FMR LLC grew its stake in Charles River Laboratories Intl. by 22.7% in the 4th quarter. FMR LLC now owns 1,910,814 shares of the medical research company’s stock valued at $291,896,000 after buying an additional 353,231 shares during the last quarter. Iridian Asset Management LLC CT acquired a new position in shares of Charles River Laboratories Intl. during the 4th quarter worth approximately $32,215,000. Alyeska Investment Group L.P. grew its position in shares of Charles River Laboratories Intl. by 66.0% during the 4th quarter. Alyeska Investment Group L.P. now owns 396,692 shares of the medical research company’s stock worth $60,599,000 after purchasing an additional 157,716 shares in the last quarter. Public Employees Retirement Association of Colorado grew its position in shares of Charles River Laboratories Intl. by 2,050.2% during the 3rd quarter. Public Employees Retirement Association of Colorado now owns 163,199 shares of the medical research company’s stock worth $21,603,000 after purchasing an additional 155,609 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Charles River Laboratories Intl. by 1,215.7% during the 4th quarter. Point72 Asset Management L.P. now owns 156,872 shares of the medical research company’s stock worth $23,964,000 after purchasing an additional 144,949 shares in the last quarter. Institutional investors and hedge funds own 95.78% of the company’s stock.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Thursday. KeyCorp upped their target price on shares of Charles River Laboratories Intl. from $151.00 to $162.00 and gave the company an “overweight” rating in a report on Monday, December 9th. Citigroup upped their target price on shares of Charles River Laboratories Intl. from $185.00 to $200.00 and gave the company a “buy” rating in a report on Wednesday. Morgan Stanley upped their target price on shares of Charles River Laboratories Intl. from $156.00 to $176.00 and gave the company an “equal weight” rating in a report on Wednesday. Finally, Barclays reaffirmed a “hold” rating and issued a $170.00 target price on shares of Charles River Laboratories Intl. in a report on Wednesday. Seven research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. Charles River Laboratories Intl. presently has an average rating of “Buy” and an average price target of $169.33.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Further Reading: Guidelines for Successful Channel Trading

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.